1.Pervasive Developmental Disorders and Autism Spectrum Disorders: Are These Disorders One and the Same?.
Masaru TATENO ; Saya KIKUCHI ; Kumi UEHARA ; Kyoko FUKITA ; Naoki UCHIDA ; Ryuji SASAKI ; Toshikazu SAITO
Psychiatry Investigation 2011;8(1):67-70
The concept of pervasive developmental disorders (PDD) and autism spectrum disorders (ASD) closely resemble each other. Both ICD-10 and DSM-IV use the term PDD. The authors surveyed the perception of PDD/ASD and attitudes toward terminology. The subjects of this study were 205 medical/social-welfare professionals working in fields relating to developmental disorders. Questionnaires were mailed to site investigators at the collaborating institutes. With regard to what the scope of ASD and PDD encompasses, the answers were almost equally divided among three views: ASD and PDD are the same, PDD is wider in scope and ASD is wider. The terms PDD and autism were used in slightly different ways depended upon the situation. Our results demonstrate that the parameters of PDD and ASD are unclear and that the terms related to PDD/ASD are often used differently. Further studies are required to develop more clear and reliable diagnostic criteria for PDD.
Academies and Institutes
;
Asperger Syndrome
;
Autistic Disorder
;
Child
;
Autism Spectrum Disorder
;
Diagnostic and Statistical Manual of Mental Disorders
;
Humans
;
International Classification of Diseases
;
Postal Service
;
Surveys and Questionnaires
;
Research Personnel
2.Effects of mosapride on motility of the small intestine and caecum in normal horses after jejunocaecostomy.
Kouichi OKAMURA ; Naoki SASAKI ; Takuya KIKUCHI ; Aya MURATA ; Inhyung LEE ; Haruo YAMADA ; Hisashi INOKUMA
Journal of Veterinary Science 2009;10(2):157-160
The purpose of the present study was to evaluate the prokinetic effects of mosapride with non-invasive assessment of myoelectrical activity in the small intestine and caecum of healthy horses after jejunocaecostomy. Six horses underwent celiotomy and jejunocaecostomy, and were treated with mosapride (treated group) at 1.5 mg/kg per osos once daily for 5 days after surgery. The other six horses did not receive treatment and were used as controls (non-treated group). The electrointestinography (EIG) maximum amplitude was used to measure intestinal motility. Motility significantly decreased following surgery. In the treated group, the EIG maximum amplitude of the small intestine was significantly higher than in the controls from day 6~31 after treatment. These findings clearly indicate that mosapride could overcome the decline of intestinal motility after jejunocaecostomy in normal horses.
Anastomosis, Surgical/veterinary
;
Animals
;
Benzamides/*pharmacology
;
Cecum/*drug effects/physiology
;
Electrophysiology
;
Female
;
Gastrointestinal Agents/*pharmacology
;
Gastrointestinal Motility/*drug effects
;
Horses/*physiology/surgery
;
Intestine, Small/*drug effects/physiology/surgery
;
Jejunostomy/veterinary
;
Male
;
Morpholines/*pharmacology